Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.77 |
| ▸ | FLT3 | P36888 | 5/20 | 0.77 |
| ▸ | KDR | P35968 | 3/20 | 0.77 |
| ▸ | AXL | P30530 | 3/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.77 |
| ▸ | KIT | P10721 | 2/20 | 0.77 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.77 |
| ▸ | FLT1 | P17948 | 2/20 | 0.77 |
| ▸ | MST1R | Q04912 | 2/20 | 0.77 |
| ▸ | PLK4 | O00444 | 1/20 | 0.77 |
| ▸ | STK25 | O00506 | 1/20 | 0.77 |
| ▸ | CIT | O14578 | 1/20 | 0.77 |
| ▸ | AURKA | O14965 | 1/20 | 0.77 |
| ▸ | CHUK | O15111 | 1/20 | 0.77 |
| ▸ | MUSK | O15146 | 1/20 | 0.77 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.77 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.77 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363123 | 0.95 | MET (0.75) | METFLT3KDRAXLPDGFRB | |
| SCHEMBL12510585 | 0.89 | MET (0.72) | METFLT3KDRAXLPDGFRB | |
| SCHEMBL1877060 | 0.88 | MET (0.84) | METFLT3KDRAXLPDGFRB | |
| SCHEMBL371582 | 0.88 | FLT3 (0.68) | METFLT3KDRAXLPDGFRB | |
| SCHEMBL29693576 | 0.88 | MET (0.74) | MET | |
| SCHEMBL372073 | 0.88 | MET (0.74) | MET | |
| SCHEMBL14670933 | 0.88 | FLT3 (0.77) | METFLT3KDRAXLPDGFRB | |
| Foretinib SCHEMBL371804 | 0.87 | MET (1.00) | METFLT3KDRAXLPDGFRB | |
| SCHEMBL29693444 | 0.87 | MET (1.00) | METFLT3KDRAXLPDGFRB | |
| Foretinib SCHEMBL30498609 | 0.87 | MET (1.00) | METFLT3KDRAXLPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | claimed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | MET 1/4885FLT3 149/4885KDR 32/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | MET 312/4885FLT3 321/4885KDR 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.